Syndesi Therapeutics SA, a clinical stage biotechnology company developing novel modulators of the synaptic vesicle protein SV2A for the treatment of cognitive impairment, provides an update on the clinical development of its lead molecule, SDI-118, and announces an extension of its series A financing. With AbbVies acquisition of Syndesi, we aim to advance the research of a novel, first-in-class asset for the potential treatment of cognitive impairment associated with neuropsychiatric and neurodegenerative disorders.. Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating the synaptic transmission is a promising approach to treat Alzheimer's disease and other disorders with cognitive impairment. Registration or use of this site constitutes acceptance of our Terms of Service and Privacy Policy. Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. The objective of the fund is to invest in the development of start-ups, from validation of the technology to commercial maturity. In June last year, AbbVie exercised an exclusive option for the acquisition of TeneoOne, a Teneobiosubsidiary. . The biotech notes that disruption of the synaptic connectivity is found in Alzheimers and other types of dementia. Type Clinical studies at UCB: How are medicines made and tested? Syndesi Therapeutics is a Pharmaceutical Company located in Belgium, Europe, and was founded in 2018. var path = 'hr' + 'ef' + '='; the acquisition further reinforces abbvie's neurology pipeline, as four years ago, syndesi therapeutics gained the rights to ucb's synaptic vesicle protein 2a (sv2a) programme, which aims to achieve synaptic efficiency, targeting the communication between neurons in the brain, which - most notably in alzheimer's - typically deteriorates as Johnson & Johnson Innovation JJDC Inc. (JJDC) is the strategic venture capital arm of Johnson & Johnson and a long-term investment partner to global healthcare entrepreneurs. Privacy Center | var prefix = 'ma' + 'il' + 'to'; Request Profile Update Download Data Home Profiles Pharmaceutical Company Europe Syndesi Therapeutics Syndesi Therapeutics Details Syndesi Therapeutics Contact Information Get News Stories Delivered to Your Inbox Your Email: Join Today Stay up-to-date on the latest news and information from UCB, 2007 - 2022UCB S.A., Belgium. Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by Syndesi Therapeutics - Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies, - Novel mechanism will be evaluated for the potential to mitigate synaptic dysfunction associated with cognitive deficits across a range of neuropsychiatric and neurodegenerative disorders. Do not sell my information, Bain Capital-Backed Emalex Bio Lands $250M for Pivotal Test of Tourette Drug, How To Create Digital Health Apps That Serve as Useful Tools (Not Unnecessary Work), Why Digital Health Collaborations Are the Future of Medtech, Rubiuss New Cell Therapy Strategy Runs Out of Time & Money; Workforce Is Cut by 82%, Startup Founded by Brown Undergrads Raises $14M to Improve Care for Vulnerable Seniors, AMA: CMS 2023 Physician Fee Schedule Would Create Financial Instability, Carta Healthcare Rakes in $20M with Hopes of Selling its Tech to More Hospitals, CVS, Walgreens Will Pay $10 Billion Total To Settle Opioid-Related Lawsuits. About Syndesi Therapeutics Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate. UCB - Inspired by patients. UCBs Neuroscience researchers in Belgium have designed a unique class of novel SV2A modulators. Anthos Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of genetically and pharmacologically validated innovative therapies to advance care for people living with cardiovascular and metabolic (CVM) diseases. 2022 Breaking Media, Inc. All rights reserved. Dispersion and Wet Milling Technology for Pharmaceuticals, Supply Chain Support Services for Life Science Companies, Thank you for subscribing to Pharmaceutical Technology, The leading site for news and procurement in the pharmaceutical industry, Receive our newsletter - data, insights and analysis delivered to you. The company's drugs can modulate the synaptic vesicle protein to handle the transmission between neurons in the brain to effectively treat Alzheimer's and other disorders with cognitive impairment, enabling healthcare providers to treat these diseases with the right therapy at their disposal. Revolutionary intracellular screening platform creates new opportunities to discover first-in-class therapeutics to address challenging disease targets. Therapeutic botox accounted for $2.45 billion in 2021 sales, making it the companys top neuro product. Cleary Gottlieb Steen & Hamilton LLP acted as legal counsel to AbbVie. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. Syndesi Therapeutics was established to develop a series of novel, pro-cognitive small molecule SV2A modulators licensed from UCB. The pharmaceutical giant is taking steps to remedy that deficiency by striking a deal: the acquisition of a UCB spinout thats already reached the clinic with a drug that takes a new approach to brain disorders and has potential applications that include Alzheimers disease. document.getElementById('cloak45869').innerHTML = ''; Ferrous(II) glycine sulphate complex (Ferro Sanol), Plain language summaries of study results, Access to Patient-Level Clinical Study Data, Plain Language Summaries of research results, Registration and Results Reporting on Public Registries, Cimzia - Axial spondyloarthritis (axSpA), Privacy Policy for Healthcare Professionals, Syndesi Therapeutics to leverage UCBs expertise in neurology drug discovery to develop potential therapeutics in cognitive disorders with a first-in-class mechanism, Series A financing of 17 M from a syndicate of Belgian and international investors. Follow us on Twitter: @UCB_news. Novo Seeds is the early-stage investment arm of Novo Holdings (www.novoholdings.dk). Sirona's current pipeline includes further cosmetic related products for cell preservation and repair, keloid therapy, scar therapy, anti-aging, anti-wrinkle, and . They are also entitled to get further contingent payments of up to $870m on meeting specific pre-set milestones. Synaptic dysfunction is believed to underlie the cognitive impairment seen in multiple neuropsychiatric and neurodegenerative disorders. SV2A plays a central role in synaptic transmission (connections between neurons). President of Humanas primary care, Rene Buckingham, addresses the needs of many seniors facing multiple diagnoses and barriers to high-quality care. . Pipeline Prospector delivers free access to a database of Neurology drugs under clinical trials which made headlines done by Syndesi Therapeutics There is a major unmet need for new therapies that can help improve cognitive function in patients suffering from difficult-to-treat neurologic diseases, Hudson said in a prepared statement. With the acquisition, AbbVie will gain ownership of Syndesis portfolio of new synaptic vesicle protein 2A (SV2A) modulators, including its lead small molecule, SDI-118. About Syndesi Therapeutics Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Regulating synaptic transmission represents a promising approach to treating Alzheimer's Disease and other disorders with cognitive impairment. Syndesi Therapeutics SA, a clinical stage biotechnology company developing novel modulators of the synaptic vesicle protein SV2A for the treatment of cognitive impairment, announces results from two Phase I studies of its lead compound SDI-118, supporting further development of this promising molecule. More. With more than 7500 people in approximately 40 countries, the company generated revenue of 4.2 billion in 2016. AbbVies portfolio and pipeline is thin on brain drugs, particularly in the area of neurodegeneration. and we will provide you with regular updates. In the life science sector, SRIW is investor in more than 30 companies such as I.B.A., Celyad, or Ogeda of which it recently exited. Syndesi Therapeutics serves customers worldwide. Syndesi Therapeutics is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Four years after spinning out from Belgium's UCB, Syndesi Therapeutics and its SV2A modulator programme has been bought. The anchor of AbbVies neuroscience portfolio is probably botox. Novo Holdings is a private limited liability company wholly owned by the Novo Nordisk Foundation. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. The VIVES Louvain Technology Fund (www.vivesfund.com) is a multi-sector technology fund which invests in the spin-offs of the Universit catholique de Louvain (UCL) and start-ups in Belgium and neighboring countries. The Company's approach is aimed at treating Alzheimer's Disease and other disorders with cognitive impairment. The companys drugs are small molecules that modulate synaptic transmission, which is the communication that happens between neurons in the brain. The acquisition further reinforces AbbVie's neurology pipeline, as four years ago, Syndesi Therapeutics gained the rights to UCB's. Latest news. Clinical trial records show the drug is currently in two Phase 1b tests, one enrolling elderly patients with cognitive decline and the other testing the drug candidate in adults in remission from depression. Syndesi Therapeutics' lead pipeline candidate is SDI-118. Syndesi, which takes its name from the Greek word for connection, develops drugs that target synaptic vesicle protein 2A (SV2A), a protein that plays a key role in regulating neurotransmission. The product, which came to AbbVie in the 2020 Allergan acquisition, is approved for a range of therapeutic indications that include treating muscle spasticity from a stroke or other injury, as well as preventing migraine headaches. VIVES II is funded by a dozen leading Belgian and European investors such as the EUROPEAN INVESTMENT FUND (EIF), SFPI-FPIM, BNP PARIBAS FORTIS PRIVATE EQUITY BELGIUM, BPI FRANCE (France), ING BELGIUM, SOFINA, AXA BELGIUM, BELFIUS, IRD (France), NIVELINVEST, REGION BRUXELLES CAPITAL and by SOPARTEC. SRIW Socit Rgionale d'Investissement de Wallonie (www.sriw.be) provides equity and/or debt to companies that generate added value and employment in Wallonia. Syndesi will build on a rich legacy of work by UCB to further develop these novel SV2A modulators to investigate their potential to improve cognition in diseases such as Alzheimers Disease, other dementias and cognitive impairment associated with schizophrenia. The pharmaceutical industry's most comprehensive news and information delivered every month. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. UCB identified novel modulators of SV2A that show pro-cognitive properties in preclinical models. The mechanism is currently being evaluated . . Within the life science sector, specific areas of interest to Fountain include specialty pharma, medical devices, biotechnology and diagnostics. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed. www.jjdc.com. When it comes to contacting clinicians and patients, the hospital switchboard can be just as [], AbbVie, alzheimer's disease, Clinical Trials, deals, life sciences M&A, neuroscience, North Chicago, UCB. Contact Email info@syndesitherapeutics.com Phone Number +32 10 280 238 Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). On Mar 2, 2022 AbbVie announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. Prilenia Therapeutics. About Syndesi Therapeutics Syndesi Therapeutics (www.syndesitherapeutics.com) has been established at the Centre d'Entreprises et d'Innovation (CEI) in Louvain-la-Neuve and will have a presence at the JLINX incubator facilities to access expertise at the Janssen campus in Beerse, Belgium. Milestone payments could bring shareholders of the biotech up to $870. Milestone payments could bring shareholders of the biotech up to $870 million more. Synaptic dysfunction, with the consequent disruption of connectivity bet ween brain regions, underlies cognitive impairment seen in multiple CNS . Under the terms of the agreement, AbbVie will pay Syndesi shareholders a $130 million upfront payment with the potential for Syndesi shareholders to receive additional contingent payments of up to $870 million based on the achievement of certain predetermined milestones. AbbVies Syndesi acquisition gives the pharma company an additional shot at neurodegeneration. AbbVie has acquired Belgium-based company Syndesi Therapeutics in a deal worth up to $1bn, expanding its neuroscience portfolio. Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). flanders.bio wants to improve your user experience on this website. Though the deal, AbbVie will gain access to Syndesis portfolio of SV2A modulators. For more information about AbbVie, please visit us atwww.abbvie.com. The mechanism is now being studied to potentially treat cognitive impairment and other symptoms linked to various neurodegenerative and neuropsychiatric diseases such as major depressive disorder and Alzheimers disease. Join our mailing list. Read More Our Science Learn More. AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at up to $1 billion. . This investment group formed Syndesi in 2017; the startup licensed SDI-118 from UCB in 2018. Unlike, UCB is the world leader in SV2A research, having discovered and developed two major anti-epileptic drugs treating patients around the world. Back to companies Fountain Healthcare Partners (www.fh-partners.com) is a life science focused venture capital fund with 176 million ($200 million) under management. 2007 -2022 UCB S.A., Belgium. There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. With AbbVies acquisition of Syndesi, we aim to advance the research of a novel, first-in-class asset for the potential treatment of cognitive impairment associated with neuropsychiatric and neurodegenerative disorders.. You need JavaScript enabled to view it. Syndesi, which is based in Belgium, aims to treat brain disorders by reducing the symptoms of cognitive impairment. Driven by science. Syndesi's Series A financing was co-led by Novo Holdings together with Fountain Healthcare Partners, with participation from Johnson & Johnson Innovation JJDC, Inc., SRIW (Socit Rgionale d'Investissement de Wallonie), V-Bio Ventures and Vives Fund, along with UCB Ventures. All rights reservedLast updated on:April, 07, 2022, Syndesi Therapeutics is based in Belgium and will leverage UCBs neurology expertise in modulating the synaptic vesicle protein SV2A. We are deploying our platform to build a pipeline of first-in-class small molecules to address high priority cancer targets that have evaded conventional discovery approaches. Now, as part of AbbVie, the program is well positioned to move into later stages of clinical development.". Send. On March 1, 2022 AbbVie (NYSE: ABBV) reported it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio (Press release, AbbVie, MAR 1, 2022, View Source [SID1234609248]). GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis, Report bundle: Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis, Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing, Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective, ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis, PipelineReview.com is powered by La Merie Business Intelligence, For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01, La Merie Publishing - Ulrich Martin | Carrer Nria, 10, 3, 2a | 17500 Ripoll | Spain T +49-7934-6839 668 | F +49-3212-1267 572 | Email This email address is being protected from spambots. var addy45869 = 'info' + '@'; All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. Get the latest industry news first when you subscribe to our daily newsletter. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Syndesi has an exclusive, worldwide license from UCB to develop and commercialise a series of novel, pro-cognitive SV2A modulators. The firm deploys the majority of its capital in Europe, with the balance in the United States. North Chicago, Illinois-based AbbVie announced Tuesday that it paid $130 million up front to acquire Syndesi Therapeutics. We make long term investments in early stage companies in the US and Europe. The Belgian life science ecosystem is particularly vibrant and we realised that it was the right environment to promote this research as part of our biotech model approach., Jonathan Savidge, PhD CEO of Syndesi noted Development of these small molecules that modulate the SV2A target in a distinct manner represents an intriguing new approach for the treatment of cognitive deficits since they specifically target synaptic dysfunction, a hallmark of Alzheimers Disease and other indications characterized by cognitive impairment. Cognitive impairment observed in various neuropsychiatric and neurodegenerative ailments is claimed to be triggered by synaptic dysfunction. "Le dynamisme de notre activit, combin aux avances de notre pipeline, continue de soutenir les perspectives prometteuses d'AbbVie long terme." Sur une base GAAP, le ratio de marge brute du deuxime trimestre tait de 71,4 %. MT . Bone Therapeutics is a bone cell therapy company specializing in addressing unmet medical needs in the field of orthopaedics and bone diseases. T+32.2.559.9588, isabelle.ghellynck@ucb.com.
Javascript Read Local File Without Input, Round Steel Concrete Forming Stakes, Uniform Indemnification Agreement Bank, React-export-excel Codesandbox, Enrich Financial Wellness, Samsung Type C Headphones Not Working In Smule, Port Lympne Safari Park, Alienware Aw2721d Best Settings For Warzone, Robotic Font Commercial Use, 4 Importance Of Cooperation, Objectives Of Social Studies Jss1, Example Of Vision In Psychology,